伊布替尼
伊德里希
威尼斯人
医学
慢性淋巴细胞白血病
CD20
奥比努图库单抗
美罗华
免疫学
疾病
肿瘤科
内科学
重症监护医学
白血病
淋巴瘤
作者
Michael Hallek,Tait D. Shanafelt,Barbara Eichhorst
出处
期刊:The Lancet
[Elsevier]
日期:2018-04-01
卷期号:391 (10129): 1524-1537
被引量:226
标识
DOI:10.1016/s0140-6736(18)30422-7
摘要
Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management.
科研通智能强力驱动
Strongly Powered by AbleSci AI